St. Petersburg Times
Special report
Video report
  • For their own good
    Fifty years ago, they were screwed-up kids sent to the Florida School for Boys to be straightened out. But now they are screwed-up men, scarred by the whippings they endured. Read the story and see a video and portrait gallery.
  • More video reports
Multimedia report
Print Email this storyEmail story Comment Email editor
Fill out this form to email this article to a friend
Your name Your email
Friend's name Friend's email
Your message
 

Hung jury in federal Vioxx trial

A new panel will hear the case against Merck. Recent allegations about withholding safety data could be raised.

Associated Press
Published December 13, 2005


HOUSTON - The nation's first federal Vioxx trial ended Monday with a hung jury, but the case involving the 2001 death of a St. Augustine man who took the once-popular painkiller for a month will be retried, a judge said.

The mistrial leaves Vioxx's maker, Merck & Co., with the prospect of facing a new jury that could hear allegations that the company withheld information from the New England Journal of Medicine about a 2000 Vioxx study so the drug would appear safer than it was. Merck shares fell almost 3 percent as the trial's outcome shook investors worried about the company's liability in the thousands of pending Vioxx cases.

About 20-million people took Vioxx before Merck withdrew what had become a $2.5-billion seller from the market last year when a separate, longer-term study showed it could double the risk of heart attack or stroke if taken for 18 months or longer.

"You can't lie to people like the New England Journal of Medicine and get away with it," said plaintiff's attorney Jere Beasley. "We look forward to the next trial."

Merck lead attorney Phil Beck said last week's revelations from the medical journal would be a "nonissue" in a retrial and that Merck supplied all the updated safety data to the Food and Drug Administration before the journal article was published.

The jury's inability to reach a unanimous verdict apparently was unrelated to the journal revelations that came late last week, after deliberations began. The journal reported Thursday that authors of a report about the Merck-funded study - including Merck's head of clinical trials and a key witness for Merck, Dr. Alise Reicin - omitted three patients' heart attacks in the data they submitted to the journal, making it appear that Vioxx caused four times, rather than five times, as many heart attacks as the painkiller naproxen.

The 2000 study, called VIGOR, has figured heavily in the first three Vioxx trials to reach juries - one in a Texas state court that Merck lost, another in its home state of New Jersey that the company won, and in the federal case held in Houston.

Merck disclosed the full number of heart attacks to the FDA that year.

"The FDA based all of its safety decisions and labeling and approval decisions ... on the full updated information," Beck said, meaning the data that said Vioxx caused five times as many heart attacks as naproxen.

The mistrial means Merck gained no momentum in its battle against about 7,000 pending state and federal Vioxx lawsuits and potentially billions of dollars in payouts.

The nine-member jury was about 20 minutes into its fourth day of deliberations when U.S. District Judge Eldon Fallon called the jurors in and reminded them they had agreed Saturday to reach a verdict in a "reasonable time."

"It has now been a reasonable time. We cannot get a verdict," Fallon said, declaring a mistrial. Federal litigation requires a unanimous verdict.

Merck attorney Beck said Fallon gave the jury enough time.

"At some point if you are a judge, you have to make a tough call and you say, you know what? They have been at it long enough and if I make them stay any longer, then people are going to be questioning whether the verdict ... really reflects the consent of nine people or not."

The jury couldn't decide whether Merck was liable in Richard "Dicky" Irvin's 2001 death and whether the company failed to issue safety warnings that the drug could have serious cardiovascular side effects.

Merck argued that Vioxx was not a factor in Irvin's death because he took the drug for about a month, and the long-term study that led to the drug's withdrawal last year showed dangers only after 18 months' use. The company blamed his death on clogged arteries and a blood clot that led to the heart attack.

Irvin, a former college football player who managed a wholesale seafood company in St. Augustine, got a prescription for Vioxx from his son-in-law, an emergency room physician, without a medical checkup.

His wife, Evelyn Irvin Plunkett, alleged that Vioxx - which inhibits an enzyme that promotes inflammation and thins the blood - led to the clot formation.

She said Monday she thought she had to convince a jury that Vioxx was the culprit.

"I knew in my heart my husband had died because of Vioxx, and I had to push forward (with a lawsuit) because of that," Plunkett said outside the courtroom. "A lot of people have been injured, hurt, died because of that drug."

Beasley said the plaintiff's team hopes to present the journal allegations and more evidence in a retrial than the Houston jury heard.

"We are not going to quit," Beasley said.

Beck said Merck was confident in its defense, even though the company rested its case without calling a cardiologist to testify.

In the first case, a Texas state jury slapped Merck with a $253-million verdict, which will be reduced to $26.1-million at most because of state caps on punitive damages. Merck is expected to appeal.

In November, jurors in Merck's home state of New Jersey absolved Merck of liability, awarding nothing to an Idaho man who survived a heart attack after taking the drug intermittently for two months.

Fallon has said he intends to meet with lawyers about the possibility of a global settlement after the fourth federal trial wraps up.

The judge said he would confer with attorneys next week to set a retrial date. Beck said the retrial would likely be in February in its original venue of New Orleans. The trial was moved to Houston because of hurricane damage. The next state trial is scheduled for Feb. 27 in New Jersey.

Merck shares fell 72 cents, or 2.5 percent, to close at $28.41 Monday on the New York Stock Exchange.

[Last modified December 13, 2005, 01:30:24]


Share your thoughts on this story

[an error occurred while processing this directive]
Subscribe to the Times
Click here for daily delivery
of the St. Petersburg Times.

Email Newsletters

ADVERTISEMENT